ICON (ICLR) Earnings Date & Reports

Key Takeaways

• ICON plc reported third-quarter 2026 revenue of $2,024.8 million, down 2.9% year over year but ahead of the roughly $2.01 billion consensus estimate.
• Adjusted diluted EPS (earnings per share) came in at $2.66, above the consensus estimate of roughly $2.62–$2.64 and up 3.9% sequentially.
• Net business wins reached $3,150 million with a book-to-bill ratio of 1.56x, lifting closing backlog to a record $24.5 billion.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $336.9 million, or 16.6% of revenue, down 13.1% year over year on continued margin pressure.
• The company updated full-year 2026 guidance, now targeting revenue of $8,100–$8,200 million and adjusted diluted EPS of $10.35–$10.65.
• ICON repurchased $400 million of stock in the quarter and increased its buyback authorization to $750 million.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available on our platform.
• Interested in automated trading ideas? Explore Trending AI Robots to see how AI-driven strategies are scanning the market.

Earnings Context and Why It Matters

ICON plc (NASDAQ: ICLR) is a world-leading clinical research organization (CRO) that helps pharmaceutical, biotechnology, and medical device companies run clinical trials from early development through commercialization. Its quarterly results are a closely watched barometer for research and development (R&D) spending across the broader life-sciences industry. This report matters because it arrives during a period when demand for clinical outsourcing has rebounded, even as higher pass-through costs and a competitive pricing environment continue to squeeze profitability. For investors, the quarter offers a critical read on whether ICON can sustain its strong commercial momentum and rebuild margins, two factors that will shape how the stock is valued heading into 2027.

Reported Results

For the third quarter ended September 30, 2026, ICON reported revenue of $2,024.8 million, a decrease of 2.9% from the prior-year period, or 2.5% on a constant-currency basis. This topped the consensus estimate of approximately $2.01 billion. GAAP (Generally Accepted Accounting Principles) net income was $122.1 million, or $1.58 per diluted share, compared with a loss of $(3.67) per diluted share a year earlier, when results were weighed down by goodwill and non-financial asset impairments.

Adjusted diluted EPS was $2.66, above the consensus estimate of roughly $2.62–$2.64 and up 3.9% from the prior quarter. Adjusted net income was $205.8 million. Adjusted EBITDA was $336.9 million, representing a margin of 16.6%, down 13.1% year over year. The margin decline reflects elevated pass-through activity and a shift in business mix, which have pressured profitability even as revenue and bookings remain strong.

Commercial execution stood out. Gross bookings rose 26.9% year over year to $3,789 million, with cancellations of $639 million, yielding net business wins of $3,150 million and a book-to-bill of 1.56x. Closing backlog reached $24.5 billion, up 4.8% sequentially. Free cash flow was $302.4 million for the quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. If you are looking to streamline your research and surface actionable ideas across sectors like healthcare and clinical research, the AI Screener offers a practical starting point.

Market Reaction and Investor Sentiment

Investor reaction around ICON's report has been shaped by the tension between exceptional bookings and persistent margin compression. The earnings beat on both the top and bottom lines, combined with record backlog and a raised buyback authorization, provided a supportive backdrop. At the same time, the year-over-year decline in adjusted EBITDA and the lower full-year margin outlook have kept sentiment measured, as investors weigh whether pass-through activity and business mix shifts will continue to dilute profitability. The stock has historically been sensitive to guidance revisions and book-to-bill trends, making the updated full-year range and commentary on margin trajectory key swing factors for the shares.

Forward Outlook and Key Factors to Monitor

ICON's updated full-year 2026 guidance points to revenue of $8,100–$8,200 million and adjusted diluted EPS of $10.35–$10.65, reflecting sustained operational progress alongside higher pass-through activity. Management struck a confident tone about delivering revenue growth and meaningful earnings progression in 2027 and beyond, supported by an AI-enabled digital platform that customers increasingly cite as a driver of productivity and speed.

Looking ahead, investors should watch several factors closely. First, the trajectory of adjusted EBITDA margin will be central: whether pass-through activity stabilizes and business mix improves will determine whether profitability can recover toward prior levels. Second, backlog conversion and the sustainability of the 1.56x book-to-bill ratio will indicate whether demand momentum can be maintained through 2027.

Third, capital allocation remains in focus after $400 million of buybacks and a $750 million authorization increase, alongside a $2.15 billion investment-grade bond issuance used to refinance debt. Finally, broader industry dynamics, including biotech funding conditions and pharmaceutical R&D spending trends, will continue to influence award activity. These factors, rather than any single quarter's figures, are likely to define how the market values ICON over the coming year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations